Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: | Recruiting |
---|---|
Conditions: | Ovarian Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/27/2019 |
Start Date: | May 12, 2017 |
End Date: | June 30, 2023 |
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
This randomized phase II/III trial studies how well pegylated liposomal doxorubicin
hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian,
fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy,
such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab
and bevacizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. It is not yet known which combination will
work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian,
fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy,
such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab
and bevacizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. It is not yet known which combination will
work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
PRIMARY OBJECTIVES:
I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of
experimental regimens (pegylated liposomal doxorubicin hydrochloride [pegylated liposomal
doxorubicin] [PLD] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in)
II. Estimate and compare the hazard of first progression or death (progression free survival
[PFS]) of each experimental regimen relative to the reference regimen, PLD and bevacizumab.
(Phase II study) III. Estimate and compare the hazard of death and the hazard of first
progression or death (PFS) of each experimental regimen relative to the reference regimen.
(Phase III)
SECONDARY OBJECTIVES:
I. Estimate and compare the probabilities of response rate (objective response rate [ORR],
either partial or complete response) defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version (v)1.1 criteria on each study regimen. (Phase II study) II. Estimate the
frequency and severity of adverse events as classified and graded with Common Terminology
Criteria for Adverse Events (CTCAE) in those patients who initiate their randomly assigned
study treatment. (Phase II study) III. Estimate and compare ORR in each treatment group.
(Phase III study) IV. Estimate the frequency and severity of adverse events in those patients
who initiate their randomly assigned study treatment. (Phase III study) V. Estimate and
compare mean patient reported outcome scores (PROs) as measured by National Comprehensive
Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) ovarian symptom index
(NFOSI)-18 disease-related symptoms (DRS). (Phase III study) VI. Estimate and compare the
treatment groups on the basis of the PROs: treatment side effects (TSE), function/well-being
(FWB), fatigue (Functional Assessment of Chronic Illness Therapy [FACIT]-fatigue [F]
subscale) and abdominal discomfort (FACT/Gynecologic Oncology Group [GOG]-abdominal
discomfort [AD] subscale). (Phase III study)
TRANSLATIONAL SCIENCE OBJECTIVES:
I. To determine whether biomarker levels in pre-treatment tissue, and pre- or on-treatment
peripheral blood, and stool specimens are associated with ORR, PFS and/or overall survival
(OS).
II. To determine whether changes in quantitative biomarker parameters after the first 6 and
12 weeks of therapy predict ORR, PFS and/or OS.
OUTLINE: Patients will be randomized to 1 of 3 arms.
ARM I: Patients receive pegylated liposomal doxorubicin hydrochloride intravenously (IV) over
60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15.
ARM II: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on
day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60
minutes on days 1 and 15.
ARM III: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on
day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15.
In all arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 2
years, then every 6 months for up to 3 years.
I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of
experimental regimens (pegylated liposomal doxorubicin hydrochloride [pegylated liposomal
doxorubicin] [PLD] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in)
II. Estimate and compare the hazard of first progression or death (progression free survival
[PFS]) of each experimental regimen relative to the reference regimen, PLD and bevacizumab.
(Phase II study) III. Estimate and compare the hazard of death and the hazard of first
progression or death (PFS) of each experimental regimen relative to the reference regimen.
(Phase III)
SECONDARY OBJECTIVES:
I. Estimate and compare the probabilities of response rate (objective response rate [ORR],
either partial or complete response) defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version (v)1.1 criteria on each study regimen. (Phase II study) II. Estimate the
frequency and severity of adverse events as classified and graded with Common Terminology
Criteria for Adverse Events (CTCAE) in those patients who initiate their randomly assigned
study treatment. (Phase II study) III. Estimate and compare ORR in each treatment group.
(Phase III study) IV. Estimate the frequency and severity of adverse events in those patients
who initiate their randomly assigned study treatment. (Phase III study) V. Estimate and
compare mean patient reported outcome scores (PROs) as measured by National Comprehensive
Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) ovarian symptom index
(NFOSI)-18 disease-related symptoms (DRS). (Phase III study) VI. Estimate and compare the
treatment groups on the basis of the PROs: treatment side effects (TSE), function/well-being
(FWB), fatigue (Functional Assessment of Chronic Illness Therapy [FACIT]-fatigue [F]
subscale) and abdominal discomfort (FACT/Gynecologic Oncology Group [GOG]-abdominal
discomfort [AD] subscale). (Phase III study)
TRANSLATIONAL SCIENCE OBJECTIVES:
I. To determine whether biomarker levels in pre-treatment tissue, and pre- or on-treatment
peripheral blood, and stool specimens are associated with ORR, PFS and/or overall survival
(OS).
II. To determine whether changes in quantitative biomarker parameters after the first 6 and
12 weeks of therapy predict ORR, PFS and/or OS.
OUTLINE: Patients will be randomized to 1 of 3 arms.
ARM I: Patients receive pegylated liposomal doxorubicin hydrochloride intravenously (IV) over
60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15.
ARM II: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on
day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60
minutes on days 1 and 15.
ARM III: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on
day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15.
In all arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 2
years, then every 6 months for up to 3 years.
Inclusion Criteria:
- Patients must have the psychological ability and general health that permits
completion of the study requirements and required follow up
- Women of child-bearing potential (WOCBP) must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation, and for 5 months (150 days) after the last dose
of study agent; should a woman become pregnant or suspect she is pregnant while she is
participating in this study, she should inform her treating physician immediately
- Submission of tumor tissue is required for all patients; investigators should check
with their site pathology department regarding release of biospecimens before
approaching patients about participation in the trial
- High grade ovarian cancer, including high grade serous; clear cell; endometrioid,
grade 3; and others (adenocarcinoma, nitric oxide synthase [NOS]; mixed epithelial
carcinoma; undifferentiated carcinoma); NOTE: low grade serous, mucinous and
carcinosarcoma histologies are excluded; ovarian cancer = ovarian, fallopian tube or
primary peritoneal cancer; required data element: submission of pathology report
- Recurrent, platinum resistant ovarian cancer (defined as progression within < 6 months
from completion of platinum based therapy; the date should be calculated from the last
administered dose of platinum therapy)
- 1-2 prior regimens (including primary therapy); hormonal therapies (e.g., tamoxifen,
aromatase inhibitors) will not count toward the prior regimen limit
- Measurable disease (defined by RECIST v. 1.1) or evaluable disease (defined as solid
and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1
definitions for target lesions OR ascites and/or pleural effusion that has been
pathologically demonstrated to be disease related in the setting of cancer antigen
[CA]25 >= 2 x upper limit of normal [ULN])
- Performance status 0, 1 or 2
- Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration)
- Platelets >= 100,000/mcl (within 14 days prior to registration)
- Hemoglobin (Hgb) >= 8 g/dl (within 14 days prior to registration)
- Creatinine =< 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to
registration)
- Urine protein creatinine (UPC) ratio must be < 1.0 (within 14 days prior to
registration); if UPC ratio >= 1, collection of 24-hour urine measurement of urine
protein is recommended (24-hour urine protein level must be < 1000 mg for patient
enrollment); UPC ratio of spot urine is an estimation of the 24-hour urine protein
excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
- Total bilirubin =< 1.5 x ULN (patients with known Gilbert disease who have serum
bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration)
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or
ALT =< 5 x ULN for patients with liver involvement) (within 14 days prior to
registration)
- International normalized ratio (INR) and activated partial thromboplastin time (aPTT)
=< 1.5 x ULN (or on stable dose of therapeutic anticoagulation, such as
low-molecular-weight heparin, warfarin or rivaroxaban)
- Thyroid-stimulating hormone (TSH) within normal limits (TSH < ULN allowed in euthyroid
patients on thyroid replacement therapy)
- The patient or legally authorized representative must provide study-specific informed
consent prior to study entry and, for patients treated in the United States (U.S.),
authorization permitting release of personal health information
Exclusion Criteria:
- Patients with prior allogeneic bone marrow transplantation or prior solid organ
transplantation
- Patients who have had systemic anticancer therapy (e.g., chemotherapy, targeted
therapy) within 3 weeks prior to entering the study
- Patients who have had hormonal therapy (e.g., tamoxifen, aromatase inhibitor) within 1
week prior to entering the study
- Patients with prior treatment with anti-programmed cell death (PD)-1, anti- programmed
cell death ligand (PD-L)1 or anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4
therapeutic antibody or other similar agents
- Patients with prior treatment with bevacizumab (or any other anti vascular therapy,
e.g., cediranib) for platinum resistant recurrence; (Note: prior bevacizumab in
initial therapy and/or platinum sensitive recurrent setting is allowed)
- Patients with prior treatment with PLD
- Prior radiotherapy to the abdomen or pelvis
- Patients who have not recovered from adverse events to < grade 1 (other than alopecia)
due to agents administered more than 3 weeks earlier; however, the following therapies
are allowed:
- Hormone replacement therapy or oral contraceptives
- Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as
anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)
- Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1
- Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
- Treatment with systemic immunostimulatory agents (including, but not limited to,
interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1
- Treatment with systemic immunosuppressive medications (including, but not limited to,
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1
- Patients who have received acute, low dose, systemic immunosuppressant
medications (e.g., a one-time dose of dexamethasone for nausea or steroids as
computed tomography [CT] scan contrast premedication) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone)
for patients with orthostatic hypotension or adrenocortical insufficiency is
allowed
- Patients taking bisphosphonate therapy for symptomatic hypercalcemia within the past
28 days; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or
osteoporosis) is allowed
- Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS
metastases are excluded, with the following exceptions:
- Patients with asymptomatic untreated CNS disease may be enrolled, provided all of
the following criteria are met:
- Evaluable or measurable disease outside the CNS
- No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within
10 mm of the optic apparatus (optic nerves and chiasm)
- No history of intracranial hemorrhage or spinal cord hemorrhage
- No ongoing requirement for dexamethasone for CNS disease; patients on a
stable dose of anticonvulsants are permitted
- No neurosurgical resection or brain biopsy within 28 days prior to cycle 1,
day 1
- Patients with asymptomatic treated CNS metastases may be enrolled, provided all
the criteria listed above are met as well as the following:
- Radiographic demonstration of improvement upon the completion of CNS
directed therapy and no evidence of interim progression between the
completion of CNS directed therapy and the screening radiographic study
- No stereotactic radiation or whole-brain radiation within 28 days prior to
cycle 1, day 1
- Screening CNS radiographic study >= 4 weeks from completion of radiotherapy
and >= 2 weeks from discontinuation of corticosteroids
- Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
human antibodies
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins
- Patients requiring treatment with a receptor activator of nuclear factor kappa-B
ligand (RANKL) inhibitor (e.g. denosumab) who cannot discontinue it before treatment
with atezolizumab
- Known clinically significant liver disease, including active viral, alcoholic, or
other hepatitis; cirrhosis; fatty liver; and inherited liver disease
- Patients with past or resolved hepatitis B infection (defined as having a
negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc
[antibody to hepatitis B core antigen] antibody test) are eligible
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if
polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
- History or risk of autoimmune disease, including but not limited to systemic lupus
erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's
syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune
thyroid disease, vasculitis, or glomerulonephritis
- Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid
replacement hormone are eligible
- Patients with controlled type 1 diabetes mellitus on a stable insulin regimen, or
type 2 diabetes mellitus are eligible
- Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with
dermatologic manifestations only (e.g., patients with psoriatic arthritis would
be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out
ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency
topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%,
fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months
(not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate,
retinoids, biologic agents, oral calcineurin inhibitors; high potency or
oral steroids)
- History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
pneumonia, etc.), or evidence of active pneumonitis on screening chest computed
tomography (CT) scan; history of radiation pneumonitis in the radiation field
(fibrosis) is permitted
- Patients with active tuberculosis (TB) are excluded
- Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to
hospitalization for complications of infection, bacteremia, or severe pneumonia
- Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1
- Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1;
patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract
infection or chronic obstructive pulmonary disease) are eligible
- Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of
need for a major surgical procedure during the course of the study
- Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or
anticipation that such a live, attenuated vaccine will be required during the study
and up to 5 months after the last dose of atezolizumab
- Influenza vaccination should be given during influenza season only (approximately
October to March); patients must not receive live, attenuated influenza vaccine
within 4 weeks prior to cycle 1, day 1 or at any time during the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements
- Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this
study, but HIV-positive patients must have:
- A stable regimen of highly active anti-retroviral therapy (HAART)
- No requirement for concurrent antibiotics or antifungal agents for the prevention
of opportunistic infections
- A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable
HIV viral load on standard PCR-based tests
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 3 years, with the exception of those with a negligible risk of
metastases or death, such as carcinoma in situ of the breast or cervix
- Severe, active co-morbidity defined as follows:
- Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel
obstruction
- Patients who require parental hydration and/or nutrition
- Patients who require drainage gastrostomy tube
- Evidence of bleeding diathesis or clinically significant coagulopathy
- Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture
- History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1
month of study enrollment
- Significant cardiovascular or cerebrovascular disease including:
- Uncontrolled hypertension (systolic blood pressure [SBP] >= 150; diastolic blood
pressure [DBP] >= 90)
- History of myocardial infarction within 6 months
- Unstable angina
- New York Heart Association functional classification II, III or IV
- Baseline ejection fraction =< 50% as assessed by echocardiogram or multi-gated
acquisition (MUGA)
- Cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6
months
- Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
peripheral arterial thrombosis) within 6 months
- History of abdominal/pelvic or tracheoesophageal fistula or gastrointestinal
perforation and/or abscess within 6 months prior to initiation of treatment
- Pregnant or lactating patients
We found this trial at
730
sites
6435 Chippewa Street
Saint Louis, Missouri 63109
Saint Louis, Missouri 63109
(314) 353-1870
Principal Investigator: Jay W. Carlson
Phone: 314-353-1870
Saint Louis Cancer and Breast Institute-South City Mercy Clinic St. Louis Cancer and Breast Institute...
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Carolyn Y. Muller
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Shashikant B. Lele
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Linda R. Duska
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
3300 Gallows Road
Falls Church, Virginia 22042
Falls Church, Virginia 22042
(703) 776-4001
Principal Investigator: Michael L. Maitland
Phone: 703-208-6650
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Phone: 412-339-5294
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Kristin K. Zorn
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Dan S. Zuckerman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Phone: 412-339-5294
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Richard G. Moore
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Dan S. Zuckerman
Phone: 206-215-3086
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Heidi J. Gray
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Heidi J. Gray
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: David C. Starks
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 509-574-3535
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-486-6000
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-539-2273
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-487-7447
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Michael E. Carney
Phone: 808-678-9000
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Dan S. Zuckerman
Phone: 360-412-8958
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Mark S. Shahin
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
200-298 Avenida Doctor Pedro Albizu Campos
Aguadilla, 00603
Aguadilla, 00603
Principal Investigator: Luis Baez-Diaz
Phone: 787-997-2222
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Joyce N. Barlin
Phone: 412-339-5294
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Carolyn Y. Muller
Phone: 505-272-0530
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Dan S. Zuckerman
Phone: 907-212-6871
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: David Griffin
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
3289 Woodburn Road
Annandale, Virginia 22003
Annandale, Virginia 22003
Principal Investigator: Michael L. Maitland
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Ramey D. Littell
Phone: 877-642-4691
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Asheville, North Carolina 28816
Principal Investigator: Timothy J. Vanderkwaak
Phone: 412-339-5294
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Jane L. Meisel
Phone: 404-778-1868
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Jane L. Meisel
Phone: 412-339-5294
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
Principal Investigator: Meaghan E. Tenney
Phone: 404-303-3355
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Jane L. Meisel
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Kian Behbakht
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 206-342-6954
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Stephanie L. Gaillard
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Paul Celano
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Baltimore, Maryland 21244
Principal Investigator: Leon C. Hwang
Phone: 301-816-7218
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Principal Investigator: Roisin E. O'Cearbhaill
Phone: 212-639-5007
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: William R. Robinson
Phone: 225-381-6451
Click here to add this to my saved trials
Baton Rouge, Louisiana 70806
Principal Investigator: William R. Robinson
Phone: 225-767-0822
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Patricia S. Braly
Phone: 225-215-1353
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Steven E. Waggoner
Phone: 800-641-2422
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
Bellevue, Washington 98004
Principal Investigator: John A. Keech
Phone: 425-688-5407
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Dan S. Zuckerman
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Maria C. Bell
Phone: 218-333-5000
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Dan S. Zuckerman
Phone: 541-706-2909
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Stacy D. D'Andre
Phone: 415-209-2686
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Nicholas P. Taylor
Phone: 412-339-5294
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Maria C. Bell
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Dan S. Zuckerman
Phone: 412-339-5294
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Braselton, Georgia 30517
Principal Investigator: Andrew E. Green
Phone: 770-219-8800
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
Bridgeport, West Virginia 26330
Principal Investigator: Valerie B. Galvan Turner
Phone: 304-293-7374
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Nicole S. Nevadunsky
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Nicole S. Nevadunsky
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Nicole S. Nevadunsky
Phone: 718-379-6866
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Rabbie K. Hanna
Phone: 313-916-3721
Click here to add this to my saved trials